Jazz Pharmaceuticals plc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $4.6B+13.1% YoYTTM through 30 Jun 2026
Net Income $940.8M+68.0% YoYTTM through 30 Jun 2026
Free Cash Flow $1.6BTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| EBITDA Margin | 20.4% |
| Operating Margin | 19.5% |
| Net Margin | 20.5% |
Returns
-8.2%ROE
-3.1%ROA
12.5%ROIC
Balance Sheet Health
Debt / Equity1.24x
Current Ratio1.86x
Net Debt$2.9B
Cash & Equivalents$1.6B
Quality Metrics
Altman Z-Score2.51
Piotroski F-Score6 / 9
FCF Margin34.6%
Rule of 4037.3
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2025: $4.3B
Diluted EPS-$5.84TTMFY2025: $-5.84
Dividend
No dividend
Capital Allocation
Capex Intensity1.5%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Neuroscience | $3.1B | +6.0% | |
| Oncology | $1.1B | +2.0% |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.